Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 3/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.55 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.55 |
| ▸ | TUBB | P07437 | 2/20 | 0.55 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.55 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.55 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.55 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.55 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.55 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.55 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31461255 | 0.95 | MAPT (0.51) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL23668266 | 0.95 | MAPT (0.51) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL179725 | 0.88 | MAPT (0.60) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL31461256 | 0.88 | MAPT (0.60) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Phosphonic Acid SCHEMBL5566523 | 0.83 | MAPT (0.55) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8345041 | 0.83 | MAPT (0.55) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL27452810 | 0.81 | MAPT (0.54) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5087842 | 0.78 | MEN1 (0.55) | MAPTMEN1KMT2AP2RX4P2RX1 | |
| SCHEMBL284853 | 0.77 | HDAC3 (0.56) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4090113 | 0.77 | P2RX4 (0.56) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012705-B2 | Nonseparation assay methods | BECKMAN COULTER, INC. (US) | 2011-09-06 | — | — | US | claimed |
| US-20110183361-A1 | Nonseparation Assay Methods | BECKMAN COULTER, INC. (US) | 2011-07-28 | — | — | US | claimed |
| US-RE49466-E1 | Solution phase homogeneous assays | BECKMAN COULTER, INC. (US) | 2023-03-21 | — | — | US | disclosed |
| WO-2020028619-A1 | SPARC BASED MICROORGANISM DETECTION METHOD | BECKMAN COULTER, INC. (US) | 2020-02-06 | — | — | WO | disclosed |
| US-10036708-B2 | Solution phase homogeneous assays | BECKMAN COULTER, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| EP-2027453-B1 | NONSEPARATION ASSAY METHODS | BECKMAN COULTER INC (US) | 2017-03-15 | — | — | EP | disclosed |
| EP-2021778-B1 | NONSEPARATION ASSAY METHODS | BECKMAN COULTER INC (US) | 2017-03-15 | — | — | EP | disclosed |
| EP-2401392-B1 | SOLUTION PHASE HOMOGENEOUS ASSAYS | BECKMAN COULTER INC (US) | 2017-01-25 | — | — | EP | disclosed |
| US-20150212005-A1 | SOLUTION PHASE HOMOGENEOUS ASSAYS | BECKMAN COULTER, INC. | 2015-07-30 | — | — | US | disclosed |
| US-9029092-B2 | Solution phase homogeneous assays | BECKMAN COULTER, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-8377647-B2 | Nonseparation assay methods | BECKMAN COULTER, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-6872828-B2 | Compounds for generating chemiluminescence with a peroxidase | LUMIGEN, INC. (US) | 2005-03-29 | — | — | US | disclosed |
| US-6858733-B2 | Compounds for generating chemiluminescence with a peroxidase | LUMIGEN, INC. (US) | 2005-02-22 | — | — | US | disclosed |
| EP-1456176-A4 | IMPROVED COMPOUNDS FOR GENERATING CHEMILUMINESCENCE WITH A PEROXIDASE | LUMIGEN INC (US) | 2004-11-03 | — | — | EP | disclosed |
| EP-1456176-A1 | IMPROVED COMPOUNDS FOR GENERATING CHEMILUMINESCENCE WITH A PEROXIDASE | LUMIGEN, INC. (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20040176599-A1 | Compounds for generating chemiluminescence with a peroxidase | LUMIGEN, INC. | 2004-09-09 | — | — | US | disclosed |
| CN-1492857-A | Improved compounds for generating chemiluminescence with peroxidase | 鲁米根公司 | 2004-04-28 | — | — | CN | disclosed |
| US-20030170762-A1 | Compounds for generating chemiluminescence with a peroxidase | LUMIGEN, INC. | 2003-09-11 | — | — | US | disclosed |
| US-20030170771-A1 | Compounds for generating chemiluminescence with a peroxidase | AKHAVAN-TAFTI HASHEM (US) | 2003-09-11 | — | — | US | disclosed |
| WO-2003053934-A1 | IMPROVED COMPOUNDS FOR GENERATING CHEMILUMINESCENCE WITH A PEROXIDASE | LUMIGEN, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176599-A1 | Compounds for generating chemiluminescence with a peroxidase | LPO, MPO, GPX4 | HDAC3 4141/4885HDAC4 4295/4885HDAC1 3692/4885 |
| US-20030170762-A1 | Compounds for generating chemiluminescence with a peroxidase | LPO, MPO, GPX4 | HDAC3 4141/4885HDAC4 4295/4885HDAC1 3692/4885 |
| US-20030170771-A1 | Compounds for generating chemiluminescence with a peroxidase | LPO, MPO, GPX4 | HDAC3 4141/4885HDAC4 4295/4885HDAC1 3692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.